BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11301960)

  • 21. [Medical economics of hypertension therapy].
    Yamazaki T
    Nihon Rinsho; 2008 Aug; 66(8):1601-4. PubMed ID: 18700564
    [No Abstract]   [Full Text] [Related]  

  • 22. [Prevention of cardiovascular complications after a stroke or TIA: hypotensive and hypocholesterolemic therapy].
    Vahl AC
    Ned Tijdschr Geneeskd; 2004 Jul; 148(28):1408; author reply 1408-9. PubMed ID: 15291425
    [No Abstract]   [Full Text] [Related]  

  • 23. New guidelines for the management of hypertension: latest perspective on an old problem.
    Miller NH
    Prog Cardiovasc Nurs; 1999; 14(4):153-5, 158. PubMed ID: 10689728
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comment on IOWiG report plan. A medical decision may not be replaced].
    Vorstand der Deutschen Hochdruckliga E.V
    MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705
    [No Abstract]   [Full Text] [Related]  

  • 25. [Practical guide-lines for the treatment of hypertension].
    Kiss I; Farsang C
    Orv Hetil; 2005 Feb; 146(6):267-74. PubMed ID: 15779815
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pharmacotherapy of hypertension. How much can safely be saved?].
    Anlauf M
    MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
    [No Abstract]   [Full Text] [Related]  

  • 27. [Alfadil and heart failure--clinical conclusions do exist!].
    Lohm L; Lindh E; Frösing R
    Lakartidningen; 2003 Dec; 100(49):4112-3. PubMed ID: 14717078
    [No Abstract]   [Full Text] [Related]  

  • 28. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hypertension: guidelines from JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1).
    Cuddy ML
    J Pract Nurs; 2005; 55(4):17-21; quiz 22-3. PubMed ID: 16512265
    [No Abstract]   [Full Text] [Related]  

  • 30. [Cost-effectiveness of coronary heart disease prevention].
    Wendland G; Klever-Deichert G; Lauterbach K
    Z Kardiol; 2002; 91 Suppl 2():49-60. PubMed ID: 12436765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting.
    Amira CO; Okubadejo NU
    J Hum Hypertens; 2006 Nov; 20(11):894-7. PubMed ID: 16915299
    [No Abstract]   [Full Text] [Related]  

  • 32. Differences in medical expenditure according to drug prices.
    Ueshima H
    Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
    [No Abstract]   [Full Text] [Related]  

  • 33. 2001 Canadian hypertension recommendations. What has changed?
    Canadian Hypertension Recommendations Working Group
    Can Fam Physician; 2002 Oct; 48():1662-5. PubMed ID: 12449551
    [No Abstract]   [Full Text] [Related]  

  • 34. Blood pressure measurement and assessment of the hypertensive patient.
    Matenga JA
    Cent Afr J Med; 1997 Dec; 43(12):363-5. PubMed ID: 9631117
    [No Abstract]   [Full Text] [Related]  

  • 35. [Antihypertensive treatment. Benefits and costs].
    Jensen HA; Svendsen TL
    Ugeskr Laeger; 1993 Jan; 155(2):118-20. PubMed ID: 8421861
    [No Abstract]   [Full Text] [Related]  

  • 36. [Comrades! There must be some blood order in the field of hypertension!].
    Melander A
    Lakartidningen; 2005 Apr 4-10; 102(14):1068-70. PubMed ID: 15892478
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pharmacoeconomic issues in antihypertensive treatment].
    Saito I
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():271-5. PubMed ID: 16981554
    [No Abstract]   [Full Text] [Related]  

  • 38. [Care in hypertension: guidelines and sources of error].
    Simon G
    Orv Hetil; 2005 May; 146(18):849-52. PubMed ID: 15926631
    [No Abstract]   [Full Text] [Related]  

  • 39. [German Hypertension League update. What does the ALLHAT Study really mean?].
    MMW Fortschr Med; 2003 Jun; 145(23):45-6. PubMed ID: 12854226
    [No Abstract]   [Full Text] [Related]  

  • 40. Angiotensin receptor blockers: impact on costs of care.
    Am J Manag Care; 2005 Nov; 11(13 Suppl):S400-3. PubMed ID: 16300456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.